Search Follow us

BB Biotech (BION)

Business description

BION is a Switzerland-domiciled investment company, targeting attractive long-term returns from predominantly mid-/large-cap biotech companies with established product portfolios (sales and earnings) and promising pipeline candidates. It is benchmarked against the NASDAQ Biotech Index, but is managed bottom-up with a concentrated 20-35 stock portfolio.

Stock data

Market cap.CHF3412.6m
Last closeCHF61.60
High / Low (52 weeks)CHF74.1 / CHF60.9
Stock market listingSW, IM
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamInvestment Companies
SectorInvestment Companies

Other companies in sector Show

Aberdeen Asian Income Fund Aberdeen New Dawn Investment Trust
Aberdeen New Thai Investment Trust Aberdeen Private Equity Fund
Aberdeen Standard Equity Income Trust Aberdeen UK Tracker Trust
AcenciA Debt Strategies Acorn Income Fund
Adamas Finance Asia Alliance Trust
Altamir SCA Amphion Innovations
Atlantis Japan Growth Fund Aurelius
Bailador Tech Investments Baker Steel Resources Trust
Bankers Investment Trust (The) BioPharma Credit
BlackRock Emerging Europe BlackRock Greater Europe Investment Trust
BlackRock Hedge Selector BlackRock Latin American Inv. Trust
BMO Managed Portfolio Trust Growth Portfolio BMO Managed Portfolio Trust Income Portfolio
British Portfolio Trust Brunner Investment Trust (The)
Canadian General Investments Carador Income Fund
CFP Sanford DeLand Free Spirit Fund. Charles Stanley
City Natural Resources Conversus Capital
CQS Rig Finance Fund CVC Credit Partners European Opps
Detour Gold Deutsche Beteiligungs
Dexion Commodities Diverse Income Trust (The)
DouglasBay Capital Dunedin Enterprise Investment Trust
DW Catalyst Fund Edinburgh Worldwide Investment Trust (The)
EJF Investments European Assets Trust
European Investment Trust (The) F&C Investment Trust
F&C US Smaller Companies Fidelity Asian Values
Fidelity China Special Situations Fidelity European Values
Fidelity Japan Trust Fidelity Special Values
Finsbury Growth & Income Trust Gartmore Growth Opportunities
Gartmore Irish Growth Fund Geiger Counter Limited
Genesis Emerging Markets Fund GLI Alternative Finance
Global Resources Investment Trust Golden Prospect Precious Metals
Gulf Investment Fund Hansa Trust (HAN)
HarbourVest Global Private Equity HarbourVest Senior Loans Europe
HBM Healthcare Investments Heliad Equity Partners
Henderson Alternative Strategies Trust Henderson Far East Income
Henderson Global Trust Henderson Global Trust
Henderson International Income Trust Heptagon
HSBC Infrastructure Company Infrastructure India
International Biotechnology Trust Invesco Asia Trust
Invesco Income Growth Trust Is Private Equity
JP Morgan Private Equity Limited JPMorgan Brazil Investment Trust
JPMorgan European Smaller Companies Trust JPMorgan Global Convertibles Income Fund
JPMorgan Global Growth & Income JPMorgan Indian Investment Trust
Jupiter Green Investment Trust Jupiter UK Growth Investment Trust
Jupiter US Smaller Companies JZ Capital Partners Limited
Lazard World Trust Fund Leaf Clean Energy Company
LMS Capital Lowland Investment Company
LPeC Marble Point Loan Financing
Martin Currie Asia Unconstrained Trust Martin Currie Global Portfolio Trust
Middlefield Canadian Income Miton Global Opportunities
Miton Income Opportunities Trust Murray International Trust
New City Energy Ocean Wilsons Holdings
Odyssean Investment Trust Pacific Assets Trust
Phaunos Timber Fund Polar Capital Global Healthcare Trust
Princess Private Equity Holding PXP Vietnam Fund
Rathbone Brothers RENN Universal Growth Investment Trust
Schroder AsiaPacific Fund Schroder Global Real Estate Securities
ScotGems Scottish Oriental Smaller Companies
Securities Trust of Scotland Seneca Global Income & Growth Trust
Sigma Capital Group Standard Life Investments Property Income Trust
Standard Life Private Equity Trust Standard Life UK Smaller Companies
Strategic Equity Capital Taiwan Fund (The)
Templeton Emerging Markets Investment Trust Tetragon Financial Group
The Biotech Growth Trust The Global Sustainability Trust
The Law Debenture Corporation The Merchants Trust
The North American Income Trust The Scottish Investment Trust
Tiso Blackstar Group Toscafund Asset Management
TR European Growth Trust UK Commercial Property REIT
Utilico Emerging Markets Trust Vietnam Enterprise Investments
Vietnam Holding Asset Management Vietnam Infrastructure Fund
VinaCapital Vietnam Opportunity Fund VinaLand
Vision Opportunity China Fund Volta Finance
WAM Active WAM Capital
WAM Research Witan Investment Trust
Witan Pacific Investment Trust Worldwide Healthcare Trust
YFM Equity Partners

Company news

Investment summary

BB Biotech (BION) is a Switzerland-based closed-end fund focusing on the high-growth opportunities available in the global biotechnology space. Founded in 1993 by industry specialist Bellevue Asset Management, BION holds a concentrated (c 30–35 stocks) portfolio of biotech names, which are diversified across a range of clinical focuses. The fund’s strong record of NAV outperformance versus the headline NASDAQ Biotechnology index has suffered a setback in the past 12 months. However, the managers remain optimistic on medium-term clinical catalysts and have recently refreshed the portfolio with a number of new holdings. BION has a policy of paying c 5% of its share price annually as a dividend, which, along with a shift in the shareholder base to include more long-term investors and fewer discount players, has supported a strong re-rating in the shares. The fund has traded at an average 7.1% premium to NAV in the past 12 months.

Last updated on 25/10/2018

Latest video

Bitesize Briefings - BB Biotech

Key management

Prof. Dr. Thomas Szucs, Chairman
Daniel Koller, Head of Management Team
Claude Mikkelsen, Director of IR
Dr. Silvia Schanz , Investor Relations

Company address

Seestrasse 16
Postfach
8700 Kusnacht / Zurich
Germany
+41 44 267 67 00
View website